Susquehanna International Group’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $460K | Buy |
31,751
+7,541
| +31% | +$87.5K | ﹤0.01% | 9888 |
|
|
2025
Q4 | $233K | Buy |
+24,210
| New | +$232K | ﹤0.01% | 10537 |
|
|
2025
Q3 | – | Sell |
-15,735
| Closed | -$166K | – | 12297 |
|
|
2025
Q2 | $166K | Sell |
15,735
-3,675
| -19% | -$46.4K | ﹤0.01% | 11393 |
|
|
2025
Q1 | $292K | Buy |
+19,410
| New | +$323K | ﹤0.01% | 10120 |
|
|
2024
Q2 | – | Sell |
-27,842
| Closed | -$707K | – | 11966 |
|
|
2024
Q1 | $707K | Sell |
27,842
-38,721
| -58% | -$937K | ﹤0.01% | 7673 |
|
|
2023
Q4 | $1.51M | Buy |
66,563
+13,782
| +26% | +$285K | ﹤0.01% | 5997 |
|
|
2023
Q3 | $983K | Buy |
52,781
+44,784
| +560% | +$929K | ﹤0.01% | 6662 |
|
|
2023
Q2 | $208K | Sell |
7,997
-12,794
| -62% | -$342K | ﹤0.01% | 10192 |
|
|
2023
Q1 | $597K | Buy |
+20,791
| New | +$619K | ﹤0.01% | 8127 |
|
|
2022
Q4 | – | Sell |
-11,665
| Closed | -$332K | – | 12319 |
|
|
2022
Q3 | $278K | Buy |
+11,665
| New | +$268K | ﹤0.01% | 9983 |
|
|
2022
Q2 | – | Sell |
-12,806
| Closed | -$322K | – | 12809 |
|
|
2022
Q1 | $322K | Sell |
12,806
-1,258
| -9% | -$38.4K | ﹤0.01% | 10098 |
|
|
2021
Q4 | $504K | Buy |
14,064
+5,926
| +73% | +$237K | ﹤0.01% | 9196 |
|
|
2021
Q3 | $346K | Buy |
8,138
+643
| +9% | +$26.5K | ﹤0.01% | 10268 |
|
|
2021
Q2 | $324K | Sell |
7,495
-993
| -12% | -$42.3K | ﹤0.01% | 10598 |
|
|
2021
Q1 | $346K | Buy |
8,488
+3,989
| +89% | +$151K | ﹤0.01% | 10314 |
|
|
2020
Q4 | $204K | Sell |
4,499
-4,629
| -51% | -$176K | ﹤0.01% | 9999 |
|
|
2020
Q3 | $323K | Buy |
+9,128
| New | +$330K | ﹤0.01% | 8548 |
|
|
2020
Q2 | – | Sell |
-17,923
| Closed | -$591K | – | 10064 |
|
|
2020
Q1 | $518K | Sell |
17,923
-23,797
| -57% | -$963K | ﹤0.01% | 6862 |
|
|
2019
Q4 | $2.16M | Sell |
41,720
-8,864
| -18% | -$515K | ﹤0.01% | 4195 |
|
|
2019
Q3 | $2.78M | Buy |
50,584
+38,362
| +314% | +$1.97M | ﹤0.01% | 3612 |
|
|
2019
Q2 | $496K | Buy |
+12,222
| New | +$446K | ﹤0.01% | 7276 |
|
|
2019
Q1 | – | Sell |
-7,554
| Closed | -$259K | – | 8753 |
|
|
2018
Q4 | $254K | Buy |
+7,554
| New | +$273K | ﹤0.01% | 7307 |
|
|
2018
Q3 | – | Sell |
-18,265
| Closed | -$722K | – | 9145 |
|
|
2018
Q2 | $584K | Buy |
+18,265
| New | +$752K | ﹤0.01% | 6478 |
|
|
2018
Q1 | – | Sell |
-3,971
| Closed | -$224K | – | 9262 |
|
|
2017
Q4 | $214K | Buy |
+3,971
| New | +$220K | ﹤0.01% | 8159 |
|
|
2017
Q1 | – | Sell |
-26,407
| Closed | -$1.26M | – | 8873 |
|
|
2016
Q4 | $1.29M | Buy |
+26,407
| New | +$1.22M | ﹤0.01% | 4982 |
|
|
2016
Q2 | – | Sell |
-42,400
| Closed | -$2M | – | 8492 |
|
|
2016
Q1 | $1.9M | Hold |
42,400
| – | – | ﹤0.01% | 3879 |
|
|
2015
Q4 | $1.62M | Sell |
42,400
-16,003
| -27% | -$612K | ﹤0.01% | 4467 |
|
|
2015
Q3 | $1.86M | Sell |
58,403
-21,570
| -27% | -$752K | ﹤0.01% | 4422 |
|
|
2015
Q2 | $2.64M | Buy |
79,973
+59,659
| +294% | +$2.13M | ﹤0.01% | 4108 |
|
|
2015
Q1 | $836K | Sell |
20,314
-20,181
| -50% | -$816K | ﹤0.01% | 6114 |
|
|
2014
Q4 | $1.65M | Buy |
+40,495
| New | +$1.58M | ﹤0.01% | 4820 |
|
|
2014
Q3 | – | Sell |
-10,673
| Closed | -$461K | – | 9379 |
|
|
2014
Q2 | $494K | Sell |
10,673
-15,707
| -60% | -$699K | ﹤0.01% | 7501 |
|
|
2014
Q1 | $1.08M | Buy |
26,380
+18,460
| +233% | +$686K | ﹤0.01% | 5380 |
|
|
2013
Q4 | $302K | Buy |
+7,920
| New | +$244K | ﹤0.01% | 7563 |
|
Other funds holding ANIK
CP
VCM
BFM
CM
Susquehanna International Group's ANIK Position: Q1 2026 in Review
Susquehanna International Group increased its Anika Therapeutics (ANIK) stake by 31% in Q1 2026, buying an estimated $87.5K and bringing the position to 31,751 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #9888.
Susquehanna International Group first reported a position in ANIK in Q4 2013 and has held it in 34 quarters since. The position peaked at $2.78M in Q3 2019. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.
- Susquehanna International Group held 31,751 shares of Anika Therapeutics worth $460K as of Q1 2026.
- Susquehanna International Group bought 7,541 Anika Therapeutics shares in Q1 2026, an estimated $87.5K.
- Anika Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9888 holding.
- Susquehanna International Group first reported a position in Anika Therapeutics in Q4 2013 and has held it in 34 quarters since.
- Susquehanna International Group's Anika Therapeutics position peaked at $2.78M in Q3 2019.
- 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.